Comparison · NCT04940390-5daee227
STS101 5.2 mg vs STS101 Placebo: Percentage of Subjects With Freedom From Most-Bothersome Symptom at 2 Hours Post Dose
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. STS101 5.2 mg vs STS101 Placebo: Percentage of Subjects With Freedom From Most-Bothersome Symptom at 2 Hours Post Dose. Trial comparisons, record NCT04940390-5daee227. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04940390-5daee227
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.37 | 0.336 | 0.406 | wilson | |
| Risk in group 2 | 0.325 | 0.291 | 0.36 | wilson | |
| Risk difference, group 1 minus group 2 | 0.0453 | -0.00421 | 0.0944 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.14 | 0.988 | 1.31 | log | |
| Odds ratio, group 1 over group 2 | 1.22 | 0.981 | 1.52 | log | |
| Number needed to treat, for one more participant with the outcome on STS101 5.2 mg than on STS101 Placebo | 22.1 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | STS101 5.2 mg | Subjects received a single oral dose of STS101 (dihydroergotamine nasal powder) 5.2 mg | 265 | 716 | OG000 |
| Group 2 | STS101 Placebo | Subjects received a single oral dose of Placebo for STS101 (dihydroergotamine nasal powder) | 230 | 708 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- PRIMARY
- Title
- Percentage of Subjects With Freedom From Most-Bothersome Symptom at 2 Hours Post Dose
- Description
- Subjects were prompted to document the presence of 3 symptoms (photophobia, phonophobia, and nausea) immediately before study drug administration and during the treated migraine attack.
- Time frame
- 2 Hours Post-Dose
- Population
- This analysis was conducted on the mITT population.
Source ClinicalTrials.gov
Trial
- Title
- A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine
- NCT number
- NCT04940390
- Phases
- PHASE3
- Conditions
- Migraine, Migraine With Aura, Migraine Without Aura
- Interventions
- Dihydroergotamine, Placebo
- Lead sponsor
- Satsuma Pharmaceuticals, Inc.
- Results first posted
- 2023-07-24
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04940390?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04940390-5daee227